Fortunato Michael A reported option exercise involving 970 shares of BioStem Technologies, Inc. at $0.00 for $0 on Nov 9, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Accounting Officer
Chief Accounting Officer
Filed Nov 10, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
970Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
69,634Direct
Trade date
Nov 9, 2026Option exercise
Filed
Nov 10, 2026, 4:30 PM ET1-day reporting delay
Accession
0001193125-26-455573Code M · Transaction 397090
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Option exercise970$0.00$0Trade 397091
2 transaction rows in this filing. Joint filers share the same rows.

BSEM price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BSEM · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 17, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +138%1w ago +11%1d ago +7.7%
Returns since7d30d90d180d1y

Footnotes in full

F1: These options are fully vested and exercisable. F2: These options vest according to the following schedule: 25% vested on January 4, 2024, the one year anniversary of the grant date, with the remaining options vesting in equal monthly installments over the subsequent three year period. F3: These options vest according to the following schedule: 33% vested on May 9, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. F4: These options vest according to the following schedule: 33% vested on October 13, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. F5: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. F6: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). F8: These restricted stock units vest according to the following schedule: 33% vested on May 9, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. F9: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.